Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, Glucagon, Other Aug 15 | 2019Zealand to Launch HypoPal in the US Without a Partner; Zealand Q2 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Aug 12 | 2019Novo: Updated FENIX Viewpoint; Novo Q2 '19 London Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal Aug 09 | 2019Novo: REDUCE-IT Adcom Readthrough to Oral Sema? MYL Generic Victoza Filed; Q2 '19 Earnings UpdatePurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring Aug 07 | 2019MannKind and Senseonics Q2 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery Aug 06 | 2019BD Swatch pump 510(k) withdrawn; BD CY Q2 ’19 (FY Q3 ’19) Earnings UpdatePurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Other, SGLT2i Aug 05 | 2019Forxiga DECLARE EU Approval, BTD For Provention Bio's Teplizumab (PRV-031), And MannKind/One Drop CollaborationPurchase Blast
$599
Posted in: Dual/triple agonist Aug 05 | 2019Final Tirzepatide Pivotal Trial Initiated (SURPASS-5 add-on to basal insulin)Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring Aug 01 | 2019ADA Standards of Care Update: REWIND, CGM TIR Targets, and Victoza PedsPurchase Blast
$599
Posted in: SGLT2i Jul 31 | 2019Lexicon Comments on Partnership Termination; Lexicon Q2 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Jul 30 | 2019Empa T1DM Filed with FDA; Oral GLP-1RA Advanced to Ph1; Lilly Q2 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, SGLT2i Jul 29 | 2019Sanofi Q2 '19 Earnings UpdatePurchase Blast